1. Home
  2. TBPH vs LAB Comparison

TBPH vs LAB Comparison

Compare TBPH & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • LAB
  • Stock Information
  • Founded
  • TBPH 2013
  • LAB 1999
  • Country
  • TBPH United States
  • LAB United States
  • Employees
  • TBPH N/A
  • LAB N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • LAB Biotechnology: Laboratory Analytical Instruments
  • Sector
  • TBPH Health Care
  • LAB Industrials
  • Exchange
  • TBPH Nasdaq
  • LAB Nasdaq
  • Market Cap
  • TBPH 485.8M
  • LAB 562.1M
  • IPO Year
  • TBPH N/A
  • LAB 2011
  • Fundamental
  • Price
  • TBPH $9.15
  • LAB $1.88
  • Analyst Decision
  • TBPH Buy
  • LAB Strong Buy
  • Analyst Count
  • TBPH 4
  • LAB 2
  • Target Price
  • TBPH $13.75
  • LAB $2.88
  • AVG Volume (30 Days)
  • TBPH 166.7K
  • LAB 1.7M
  • Earning Date
  • TBPH 02-24-2025
  • LAB 02-26-2025
  • Dividend Yield
  • TBPH N/A
  • LAB N/A
  • EPS Growth
  • TBPH N/A
  • LAB N/A
  • EPS
  • TBPH N/A
  • LAB N/A
  • Revenue
  • TBPH $63,192,000.00
  • LAB $155,902,000.00
  • Revenue This Year
  • TBPH $11.41
  • LAB $62.60
  • Revenue Next Year
  • TBPH $37.36
  • LAB $9.19
  • P/E Ratio
  • TBPH N/A
  • LAB N/A
  • Revenue Growth
  • TBPH 15.93
  • LAB 48.23
  • 52 Week Low
  • TBPH $7.44
  • LAB $1.21
  • 52 Week High
  • TBPH $10.44
  • LAB $3.04
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 49.84
  • LAB 51.01
  • Support Level
  • TBPH $8.35
  • LAB $1.67
  • Resistance Level
  • TBPH $8.86
  • LAB $2.14
  • Average True Range (ATR)
  • TBPH 0.29
  • LAB 0.15
  • MACD
  • TBPH -0.05
  • LAB 0.00
  • Stochastic Oscillator
  • TBPH 58.39
  • LAB 52.73

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About LAB Standard BioTools Inc.

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.

Share on Social Networks: